Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1141617

	registered interest
	date	24/07/2019
	answering body	Department for Transport
	answering dept id	27
	answering dept short name	Transport
	answering dept sort name	Transport
	hansard heading	Transport: Coastal Areas
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Transport, whether the Government has plans to allocate funding to local transport and connectivity projects in seaside towns.
	tabling member constituency	Swansea East
	tabling member printed	Carolyn Harris
	uin	281770
	answer	answer is ministerial correction date of answer 09/09/2019 answer text <p>We want to unlock the potential of every corner of the UK. Local transport funding decisions in Scotland, Wales and Northern Ireland are devolved to the Scottish Government, Welsh Assembly Government and Northern Ireland Executive, respectively. For England, we welcome proposals from Local Enterprise Partnerships, Sub-national Transport Bodies, local authorities and others on transport investment. These bodies are best placed to prioritise investments in their local areas, including to support coastal towns. When the Department for Transport considers proposals, investment decisions are made based on a rigorous and fair appraisal process that ensures spending goes to the projects and programmes where it is most needed and delivers greatest value-for-money for both taxpayers and passengers.</p><p> </p><p>The Ministry for Housing, Communities and Local Government’s Coastal Communities Fund also supports improvements in productivity in the coastal economy through projects promoting investment in innovation, infrastructure or skills provision.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 09/09/2019 12:45:26 answering member 4020 label Biography information for George Freeman
	tabling member	4480 label Biography information for Carolyn Harris

389581

	registered interest
	date	13/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Skin Cancer: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what discussions his Department has had on the availability of new treatments for (a) skin cancer patients and (b) patients with advanced melanoma.
	tabling member constituency	Swansea East
	tabling member printed	Carolyn Harris
	uin	6644
	answer	answer is ministerial correction date of answer 20/07/2015 answer text <p>A number of drugs for the treatment of skin cancers including melanoma are licensed and are available for use on the National Health Service, subject to funding decisions by the relevant commissioner.</p><p> </p><p><strong> </strong></p><p> </p><p>The National Institute for Health and Care Excellence (NICE) has recommended a number of drugs for skin cancers and melanoma and is currently developing technology appraisal guidance on several new treatments. In addition, NICE is developing a clinical guideline on the assessment and management of melanoma and its final guidance is expected to be published later this month.</p><p> </p><p> </p><p> </p><p>We take the issue of ensuring rapid access to innovative therapies very seriously, which is why we have launched an Accelerated Access Review to make recommendations to Government later in the year on speeding up access for NHS patients to innovative and cost effective new medicines, diagnostics and medical technologies.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 20/07/2015 10:15:51 answering member 4020 label Biography information for George Freeman
	tabling member	4480 label Biography information for Carolyn Harris

416750

	registered interest
	date	04/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what plans he has to ensure that patients have access to (a) nivolumab as a treatment for melanoma and (b) other new medicines that have been designated as Promising Innovative Medicines by the Medicines and Healthcare products Regulatory Agency while appraisal decisions from NICE are pending.
	tabling member constituency	Swansea East
	tabling member printed	Carolyn Harris
	uin	8491
	answer	answer is ministerial correction date of answer 14/09/2015 answer text <p>The Early Access to Medicines Scheme (EAMS) was launched in April 2014. Its purpose is to support access in the United Kingdom to unlicensed or off-label medicines representing a significant advance in treatment in areas of unmet medical need. EAMS is a 2 step process:</p><p> </p><p> </p><p> </p><p>First the Promising Innovative Medicine designation by the Medicines and Healthcare products Regulatory Agency (MHRA) is designed to give an early signal that based on early clinical evidence the medicine may be a possible candidate for EAMS and thus have the potential to be of value in areas of unmet medical need. Second, the EAMS scientific opinion by the MHRA, which we envisage will usually be towards the end of the development process, will enable prescribers and patients to decide if the EAMS medicine might be suitable for that individual patient. Nivolumab has been given a positive scientific opinion for both lung cancer and melanoma under the EAMS. For medicines granted a scientific opinion and which then receive a marketing authorisation, it is for commissioners to make funding decisions in advance of any technology appraisal guidance from the National Institute for Health and Care Excellence.</p><p> </p><p> </p><p> </p><p>The EAMS is being considered by the Accelerated Access Review currently underway.</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 14/09/2015 15:25:18 answering member 4020 label Biography information for George Freeman
	tabling member	4480 label Biography information for Carolyn Harris

416751

	registered interest
	date	04/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Nivolumab
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what the timeline is for the NICE Single Technology Appraisal of nivolumab for the treatment of melanoma.
	tabling member constituency	Swansea East
	tabling member printed	Carolyn Harris
	uin	8492
	answer	answer is ministerial correction date of answer 14/09/2015 answer text <p>The National Institute for Health and Care Excellence (NICE) currently expects to publish its first technology appraisal on the use of nivolumab (Opdivo) for the treatment of melanoma in May 2016. Further information is available at:</p><p> </p><p> </p><p> </p><p><a href="http://www.nice.org.uk/guidance/indevelopment/gid-tag515" target="_blank">www.nice.org.uk/guidance/indevelopment/gid-tag515</a></p><p> </p><p> </p><p> </p><p>NICE is also developing technology appraisal guidance on the use of nivolumab in combination with ipilimumab (Yervoy) for the treatment of melanoma and expects to issue final guidance in September 2016.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 14/09/2015 15:02:31 answering member 4020 label Biography information for George Freeman
	tabling member	4480 label Biography information for Carolyn Harris

416752

	registered interest
	date	04/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Skin Cancer: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, when he expects nivolumab to be available to NHS melanoma patients.
	tabling member constituency	Swansea East
	tabling member printed	Carolyn Harris
	uin	8493
	answer	answer is ministerial correction date of answer 14/09/2015 answer text <p>The National Institute for Health and Care Excellence (NICE) is currently developing technology appraisal guidance on the use of nivolumab (Opdivo) for the treatment of melanoma.</p><p> </p><p> </p><p> </p><p>In the absence of guidance from NICE, it is for commissioners to make decisions on whether to fund new medicines based on an assessment of the available evidence.</p><p> </p><p> </p><p> </p><p>We take the issue of ensuring rapid access to innovative therapies very seriously, which is why we have launched an Accelerated Access Review to make recommendations to Government on speeding up access for National Health Service patients to innovative and cost effective new medicines, diagnostics and medical technologies.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 14/09/2015 08:57:08 answering member 4020 label Biography information for George Freeman
	tabling member	4480 label Biography information for Carolyn Harris

431709

	registered interest
	date	23/11/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Prescription Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps his Department has taken in the last 12 months to improve access to off-patent, repurposed drugs; and what assessment it has made of the effectiveness of those steps.
	tabling member constituency	Swansea East
	tabling member printed	Carolyn Harris
	uin	17238
	answer	answer is ministerial correction date of answer 01/12/2015 answer text <p>Our policy on generic prescribing has been in place for a number of years. The policy helps ensure that patients can access the medicine that best meets their needs and it has been a key driver in the National Health Service making maximum use of off-patent drugs which are also known as generics. We have the best prescribing rate for these drugs in Europe.</p><br /><p>To support clinicians who may want to prescribe a product off-label for a patient to and improve the flow of research evidence into clinical practice, the Department hosted a Roundtable Event in February 2015. Attendees included the National Institute for Health and Care Excellence, Medicines and Healthcare products Regulatory Agency, Breast Cancer Now and other charities and discussions helped determine those non-legislative measures that could be undertaken. The Government is committed to this work and is holding a further roundtable event with charities.</p><br /> <br /> <br /> <br /> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 17153 question first answered 01/12/2015 16:29:13 answering member 4020 label Biography information for George Freeman
	tabling member	4480 label Biography information for Carolyn Harris

431711

	registered interest
	date	23/11/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Prescription Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, whether his Department's Accelerated Access Review will consider issues relating to the routine availability of off-patent, repurposed drugs.
	tabling member constituency	Swansea East
	tabling member printed	Carolyn Harris
	uin	17239
	answer	answer is ministerial correction date of answer 01/12/2015 answer text <p>The Accelerated Access Review (AAR), chaired by Sir Hugh Taylor, will make recommendations to government on reforms to accelerate access for National Health Service patients to innovative medicines and medical technologies making our country the best place in the world to design, develop and deploy these products. The terms of the reference for the review focus on faster access to innovations, which may include certain off-patent repurposed drugs, as opposed to the routine availability of medicines or medical technologies.</p><br /><p>Prior to establishing the terms of reference for the AAR, the Department reviewed evaluation reports and met with officials from previous initiatives on the uptake of innovation in the NHS including the Innovation, Health and Wealth report. As a result, building upon the lessons of previous reviews is explicit with the terms of reference of the AAR.</p><br /><p>The AAR has regular meetings with senior officials from NHS England via a steering group as recommendations are being developed. In addition, some staff from NHS England have been assigned to support the review team.</p><br /><p>Sir Hugh is still in the process of developing final recommendations which will be published in spring 2016. In his Interim Report published in October, Sir Hugh sets out a proposition on “galvanising the NHS”. This involves supporting the NHS to adopt innovation, more rapidly through better practical support, stronger incentives and the potential streamlining of local structures.</p><br /><p>The Department reviewed evaluation reports and met with officials from previous initiatives on the uptake of innovation in the NHS prior to establishing the terms of reference for the AAR. It was clear that whilst progress has been made on the uptake of innovation in the NHS there is still much to do. Sir Hugh and the head of the External Advisory Group, Professor Sir John Bell, set out the case for uptake of innovation in the recently published AAR Interim Report.</p><br /><p>The AAR has senior level contact with officials working on Lord Carter’s review of NHS efficiency to ensure that information is shared between the two teams.</p><br /> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 17266 17500 17501 17503 17504 question first answered 01/12/2015 16:58:26 answering member 4020 label Biography information for George Freeman
	tabling member	4480 label Biography information for Carolyn Harris